Santhera Pharmaceuticals Holding AG banner
S

Santhera Pharmaceuticals Holding AG
F:S3F

Watchlist Manager
Santhera Pharmaceuticals Holding AG
F:S3F
Watchlist
Price: 13.64 EUR 1.64% Market Closed
Market Cap: €31.9m

Wall Street
Price Targets

S3F Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast S3F stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for S3F is 26.86 EUR with a low forecast of 26.6 EUR and a high forecast of 27.65 EUR.

Lowest
Price Target
26.6 EUR
95% Upside
Average
Price Target
26.86 EUR
97% Upside
Highest
Price Target
27.65 EUR
103% Upside
Santhera Pharmaceuticals Holding AG Competitors:
Price Targets
RLMD
Relmada Therapeutics Inc
55% Upside
AFYA
Afya Ltd
31% Upside
ESQ
Esquire Financial Holdings Inc
12% Upside
LASR
nLIGHT Inc
-18% Downside

Revenue
Forecast

21% / Year
Past Growth
60% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
21% / Year
Past Growth
60% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

For the last 13 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 21%. The projected CAGR for the next 3 years is 60%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is S3F's stock price target?
Price Target
26.86 EUR

According to Wall Street analysts, the average 1-year price target for S3F is 26.86 EUR with a low forecast of 26.6 EUR and a high forecast of 27.65 EUR.

What is Santhera Pharmaceuticals Holding AG's Revenue forecast?
Projected CAGR
60%

For the last 13 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 21%. The projected CAGR for the next 3 years is 60%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett